诃子鞣质 | 23094-71-5

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 中文名称: 诃子鞣质
• 中文别名: 诃子鞣酸
• 英文名称: 2-[13,14,15,18,19,20,31,35,36-nonahydroxy-2,10,23,28,32-pentaoxo-5-(3,4,5-trihydroxybenzoyl)oxy-3,6,9,24,27,33-hexaoxaheptacyclo[28.7.1.04,25.07,26.011,16.017,22.034,38]octatriaconta-1(37),11,13,15,17,19,21,34(38),35-nonaen-29-yl]acetic acid
• CAS: 23094-71-5
• 化学式: C₄₁H₃₀O₂₇
• 分子量: 954.7
• InChiKey: HGJXAVROWQLCTP-UHFFFAOYSA-N

物化性质

• 熔点：
  >300℃
• 沸点：
  1610.6±65.0 °C(Predicted)
• 密度：
  2.13
• 溶解度：
  DMSO：100 mg/mL（104.75 mM；需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  68
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  447
• 氢给体数：
  13
• 氢受体数：
  27

安全信息

• WGK Germany：
  3

制备方法与用途

应用

诃子鞣酸又称为诃子鞣质，是一种多元酚类化合物，分为可水解鞣质和缩合鞣质。其中，可水解鞣质具有良好的抗氧化、抗肿瘤、抗病毒、抗菌及抗脂质过氧化等药理作用，是许多常用中药的有效成分基础。

制备方法

利用大孔树脂分离纯化诃子鞣酸。首先对7种大孔吸附树脂进行静态吸附与解吸性能考察，随后对比了HPD600和NKA-9树脂的动态吸附与洗脱效果，最终选定使用NKA-9树脂来分离纯化诃子鞣酸。

生物活性

Chebulagic acid是从果实中提取出的一种COX-LOX双重抑制剂，具有抗炎和抗感染的效果。它还是一种M2(S31N)抑制剂及抗流感病毒药物。

化学性质

诃子鞣酸来源于诃子或余甘子。

用途

主要用于含量测定、鉴定以及药理实验等。

文献信息

• NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES
  申请人：GANAPATI Gangadhara

  公开号：US20180362570A1

  公开（公告）日：2018-12-20

  The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD + levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.

  该披露提供了烟酰胺核苷酸（NR）和烟酸核苷酸（NAR）的氧化形式和还原形式的衍生物。与NR和NAR相比，NR和NAR衍生物具有更好的稳定性和生物利用度，并且可以增加细胞NAD+水平并改善线粒体功能。因此，NR和NAR衍生物对治疗线粒体疾病、与线粒体相关的疾病和症状以及其他疾病和症状具有用处。
• NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES
  申请人：MitoPower, LLC

  公开号：US20200397807A1

  公开（公告）日：2020-12-24

  The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD + levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

  该披露提供烟酰胺核糖苷（NR）、烟酰胺核糖苷的还原形式（NRH）、烟酸核糖苷（NAR）、烟酸核糖苷的还原形式（NARH）、以及它们的衍生物、组合物和用途。与NR和NAR相比，NR和NAR的衍生物具有更好的稳定性和生物利用度。NR、NRH、NAR、NARH和它们的衍生物可以增加细胞NAD+水平，增强线粒体和细胞功能以及细胞存活能力。因此，NR、NRH、NAR、NARH和它们的衍生物，无论是单独使用还是与一个或多个额外治疗剂（例如线粒体解耦蛋白抑制剂和/或PARP抑制剂）结合使用，都可用于治疗线粒体疾病、与线粒体相关的疾病和症状、代谢紊乱以及其他疾病和症状。
• Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders
  申请人：Amazentis SA

  公开号：US20170143667A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供了一些化合物或化合物前体的组合物，可用于各种治疗应用，包括治疗和/或预防与线粒体活性降低或不足有关的疾病或障碍，包括衰老或压力、糖尿病、肥胖症和神经退行性疾病等。这些化合物通常与石榴酸单宁和尿石榴素A等尿石榴素有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可以在通常健康的个体中有益地用于增加或维持代谢率，减少体脂百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS
  申请人：Amazentis SA

  公开号：US20170143666A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a. variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and uroiithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供的是包含化合物或其前体的组合物，可用于各种治疗应用，包括但不限于治疗与线粒体活性降低或不足有关的疾病或紊乱，如衰老或压力、糖尿病、肥胖症和神经退行性疾病。这些化合物通常与石榴酸单宁和尿石榴素A有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可用于一般健康的人，以增加或维持代谢率，降低身体脂肪百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof
  申请人：Amazentis SA

  公开号：US20140018415A1

  公开（公告）日：2014-01-16

  Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

  本发明涉及用于增加自噬和促进寿命的方法、化合物和组合物。所述方法、化合物和组合物涉及urolithins和urolithin前体及其使用。某些urolithins由公式I表示，而某些urolithin前体由公式IV表示。所述urolithin可以是urolithin A、urolithin B、urolithin C或urolithin D。所述urolithin前体可以是鞣花酸或鞣花酸单宁。所述方法包括化合物和组合物的体内、体外和体外使用。